These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 25846647)
1. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells. Segal CV; Koufaris C; Powell C; Gooderham NJ Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647 [TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482 [TBL] [Abstract][Full Text] [Related]
3. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
4. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490 [TBL] [Abstract][Full Text] [Related]
6. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819 [TBL] [Abstract][Full Text] [Related]
7. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen. Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190 [TBL] [Abstract][Full Text] [Related]
8. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells. Robitaille CN; Rivest P; Sanderson JT Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206 [TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
10. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Lu S; Wang A; Lu S; Dong Z Mol Cancer Ther; 2007 Jul; 6(7):2057-64. PubMed ID: 17620434 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity. Wang LG; Liu XM; Kreis W; Budman DR Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909 [TBL] [Abstract][Full Text] [Related]
12. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608 [TBL] [Abstract][Full Text] [Related]
13. Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling. Zhang Y; Won SH; Jiang C; Lee HJ; Jeong SJ; Lee EO; Zhang J; Ye M; Kim SH; Lü J Pharm Res; 2012 Jun; 29(6):1595-608. PubMed ID: 22281759 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223 [TBL] [Abstract][Full Text] [Related]
15. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276 [TBL] [Abstract][Full Text] [Related]
16. A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. Cherian MT; Wilson EM; Shapiro DJ J Biol Chem; 2012 Jul; 287(28):23368-80. PubMed ID: 22589544 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968 [TBL] [Abstract][Full Text] [Related]
19. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY; Ly LH; Peehl DM; Feldman D Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780 [TBL] [Abstract][Full Text] [Related]
20. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]